FDA approves drug for treating postpartum depression

FDA

Postpartum depression affects about 400,000 American women a year.

Posted: Mar 19, 2019 7:58 PM

TRENTON, N.J. (AP) - The U.S. Food and Drug Administration has approved the first drug specifically developed for severe depression after childbirth.

The agency on Tuesday approved Sage Therapeutics' Zulresso (ZUHL'-ress-oh), an IV drug given over 2 ½ days.

In a company-funded study of new mothers with moderate or severe postpartum depression, half the women given Zulresso had depression end within 2 ½ days, about double the rate of those in a comparison group given dummy treatments.

Postpartum depression affects about 400,000 American women a year. It's often treated with antidepressants, though they can take several weeks to help and don't always work.

Sage said Zulresso will cost $34,000 without insurance, plus costs for the stay in a hospital or infusion center.

Article Comments

Huntsville
Overcast
60° wxIcon
Hi: 61° Lo: 57°
Feels Like: 60°
Florence
Overcast
61° wxIcon
Hi: 61° Lo: 56°
Feels Like: 61°
Fayetteville
Overcast
57° wxIcon
Hi: 59° Lo: 54°
Feels Like: 57°
Decatur
Overcast
59° wxIcon
Hi: 61° Lo: 57°
Feels Like: 59°
Scottsboro
Overcast
59° wxIcon
Hi: 60° Lo: 56°
Feels Like: 59°
WAAY Radar
WAAY WAAY-TV Cam
WAAY Temperatures

Community Events